{"nctId":"NCT00821093","briefTitle":"Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2009-01"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":1123,"armGroups":[{"label":"Indacaterol 150 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 150 µg","Drug: Placebo to salmeterol"]},{"label":"Salmeterol 50 µg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Salmeterol 50 µg","Drug: Placebo to indacaterol"]}],"interventions":[{"name":"Indacaterol 150 µg","otherNames":[]},{"name":"Salmeterol 50 µg","otherNames":[]},{"name":"Placebo to indacaterol","otherNames":[]},{"name":"Placebo to salmeterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults aged ≥ 40 years\n* Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate to severe as classified by the GOLD Guidelines, 2007) and:\n\n  * Smoking history of at least 10 pack years\n  * Post-bronchodilator forced expiratory volume in 1 second (FEV1) \\< 80% and ≥ 30% of the predicted normal value at screening\n  * Post-bronchodilator FEV1/FVC (forced vital capacity) \\< 70% at screening\n\nExclusion Criteria:\n\n* Patients who have received systemic corticosteroids for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period\n* Patients requiring long-term oxygen therapy (\\> 15 h a day) for chronic hypoxemia\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening\n* Patients with concomitant pulmonary disease\n* Patients with a history of asthma\n* Patients with diabetes Type I or uncontrolled diabetes Type II\n* Any patient with lung cancer or a history of lung cancer\n* Any patient with active cancer or a history of cancer with less than 5 years disease-free survival time\n* Patients with a history of long QT syndrome or whose QTc interval (Fridericia's) measured at screening is prolonged\n* Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period\n* Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 5 Minutes to 11 Hours 45 Minutes Post-dose at the End of the Study (Week 12, Day 84)","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; 1, 2, 3, 4, and 8 hours; 11 hours 10 minutes and 11 hours 45 minutes post-dose at the end of the study (Week 12, Day 84). Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1 and FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"0.009"},{"groupId":"OG001","value":"1.41","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85)","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1 and FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":"0.009"},{"groupId":"OG001","value":"1.35","spread":"0.010"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":559},"commonTop":[]}}}